On Wednesday, Shares of Seadrill Ltd (NYSE:SDRL), lost -0.13% to $7.89.
Seadrill Limited advised that its 2015 Annual General Meeting will be held on September 18, 2015. The record date for voting at the Annual General Meeting has been set to July 24, 2014. The notice, agenda, and associated material will be distributed preceding to the meeting.
Seadrill Limited, an offshore drilling contractor, provides offshore drilling services to the oil and gas industry worldwide. The company operates through Floaters and Jack-up Rigs segments.
Shares of Cliffs Natural Resources Inc (NYSE:CLF), inclined 9.50% to $2.65, during its last trading session.
Cliffs Natural Resources, declared the commencement of an offer to purchase for cash, subject to certain terms and conditions, up to $100,000,000 aggregate principal amount of its outstanding 3.95% Senior Notes due 2018.
The Tender Offer is being made following an Offer to Purchase and a related Letter of Transmittal, both dated July 31, 2015, which set forth a more detailed description of the Tender Offer. Holders of the Notes are urged to carefully read the Tender Offer Materials before making any decision with respect to the Tender Offer.
Cliffs Natural Resources Inc. is a mining and natural resources company. The Company is a supplier of iron ore pellets to the North American steel industry from its mines and pellet plants located in Michigan and Minnesota.
Finally, OHR Pharmaceutical Inc (NASDAQ:OHRP), ended its last trade with -7.84% loss, and closed at $2.82.
OHR Pharmaceutical declared that Jason S. Slakter, MD, has been designated Chief Executive Officer, effective August 7, 2015. He succeeds CEO and founder Dr. Irach Taraporewala, who will become Chief Technology Officer and be responsible for the leadership and execution of the Company’s sustained release drug development programs, among other responsibilities. Dr. Taraporewala will continue to serve on the Company’s board of directors.
“We are delighted that Dr. Slakter has agreed to become Chief Executive Officer at Ohr. Since joining the company in 2014, he has shown tremendous leadership in moving our clinical programs forward,” stated Ira Greenstein, Chairman of the Board of Ohr Pharmaceutical. “Jason has brought noteworthy experience to Ohr, and we are confident that his combination of drug development expertise, administration ability, and transactional experience, coupled with a deep compassion for patients, will ensure that we deliver on our aims. We believe he is uniquely qualified to manage Ohr’s advancement and growth as an ophthalmology development company.”
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to improve vision outcomes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
